BR112016013714A2 - compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica - Google Patents
compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêuticaInfo
- Publication number
- BR112016013714A2 BR112016013714A2 BR112016013714A BR112016013714A BR112016013714A2 BR 112016013714 A2 BR112016013714 A2 BR 112016013714A2 BR 112016013714 A BR112016013714 A BR 112016013714A BR 112016013714 A BR112016013714 A BR 112016013714A BR 112016013714 A2 BR112016013714 A2 BR 112016013714A2
- Authority
- BR
- Brazil
- Prior art keywords
- sofosbuvir
- antiviral
- analogs
- pharmaceutical composition
- crystalline compounds
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical class N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920371P | 2013-12-23 | 2013-12-23 | |
| PCT/US2014/069123 WO2015099989A1 (en) | 2013-12-23 | 2014-12-08 | Crystalline forms of antiviral sofosbuvir analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016013714A2 true BR112016013714A2 (pt) | 2017-08-08 |
| BR112016013714A8 BR112016013714A8 (pt) | 2020-05-26 |
Family
ID=52146765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013714A BR112016013714A8 (pt) | 2013-12-23 | 2014-12-08 | compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9340568B2 (pt) |
| EP (1) | EP3086795A1 (pt) |
| JP (1) | JP2017503015A (pt) |
| KR (1) | KR20160099710A (pt) |
| CN (1) | CN105873593A (pt) |
| AP (1) | AP2016009254A0 (pt) |
| AR (1) | AR098929A1 (pt) |
| AU (1) | AU2014370299B2 (pt) |
| BR (1) | BR112016013714A8 (pt) |
| CA (1) | CA2934799A1 (pt) |
| CL (1) | CL2016001509A1 (pt) |
| CR (1) | CR20160288A (pt) |
| CU (1) | CU20160096A7 (pt) |
| DO (1) | DOP2016000141A (pt) |
| EA (1) | EA201691029A1 (pt) |
| HK (1) | HK1222334A1 (pt) |
| IL (1) | IL246066A0 (pt) |
| MD (1) | MD20160087A2 (pt) |
| MX (2) | MX2016008453A (pt) |
| MY (1) | MY178102A (pt) |
| PE (1) | PE20160750A1 (pt) |
| PH (2) | PH12019500372A1 (pt) |
| SG (1) | SG11201604818SA (pt) |
| TW (1) | TW201609785A (pt) |
| UY (1) | UY35917A (pt) |
| WO (1) | WO2015099989A1 (pt) |
| ZA (1) | ZA201604345B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| SI3524234T1 (sl) | 2014-06-13 | 2021-05-31 | Ratiopharm Gmbh | Trdne oblike sofosbuvira |
| WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
| ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
| WO2016156512A1 (en) * | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
| US20180228828A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| WO2017023714A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| US20180228827A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| WO2017029408A1 (en) * | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
| US10738071B2 (en) | 2016-03-17 | 2020-08-11 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
| CZ2016257A3 (cs) | 2016-05-05 | 2017-11-15 | Zentiva, K.S. | Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| CA3033858A1 (en) | 2016-08-19 | 2018-02-22 | Sandoz Ag | Sofosbuvir derivatives for the treatment of hepatitis c |
| CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
| JP2020502043A (ja) * | 2016-12-22 | 2020-01-23 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | ４’−チオ−２’−フルオロヌクレオシドホスファミド化合物の固体形態及びそのための調製方法及びその使用 |
| RU2656228C9 (ru) * | 2017-06-13 | 2019-04-16 | Олег Ростиславович Михайлов | Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе |
| WO2019025600A1 (en) | 2017-08-03 | 2019-02-07 | Sandoz Ag | SOFOSBUVIR HYDRATE |
| GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术（石家庄）有限公司 | 一种索磷布韦新晶型及其制备方法 |
| RU2745293C1 (ru) * | 2019-12-26 | 2021-03-23 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения кристаллической формы 8 софосбувира (варианты) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| KR101546119B1 (ko) | 2009-05-13 | 2015-08-20 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US8618076B2 (en) * | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) * | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| BR112012024884A2 (pt) * | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
| WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
-
2014
- 2014-12-04 TW TW103142194A patent/TW201609785A/zh unknown
- 2014-12-08 AU AU2014370299A patent/AU2014370299B2/en not_active Ceased
- 2014-12-08 CA CA2934799A patent/CA2934799A1/en not_active Abandoned
- 2014-12-08 AP AP2016009254A patent/AP2016009254A0/en unknown
- 2014-12-08 EP EP14819226.3A patent/EP3086795A1/en not_active Withdrawn
- 2014-12-08 PH PH12019500372A patent/PH12019500372A1/en unknown
- 2014-12-08 US US14/563,639 patent/US9340568B2/en not_active Expired - Fee Related
- 2014-12-08 MX MX2016008453A patent/MX2016008453A/es unknown
- 2014-12-08 KR KR1020167019760A patent/KR20160099710A/ko not_active Application Discontinuation
- 2014-12-08 SG SG11201604818SA patent/SG11201604818SA/en unknown
- 2014-12-08 MY MYPI2016702283A patent/MY178102A/en unknown
- 2014-12-08 MD MDA20160087A patent/MD20160087A2/ro not_active Application Discontinuation
- 2014-12-08 EA EA201691029A patent/EA201691029A1/ru unknown
- 2014-12-08 CN CN201480070460.XA patent/CN105873593A/zh active Pending
- 2014-12-08 BR BR112016013714A patent/BR112016013714A8/pt not_active IP Right Cessation
- 2014-12-08 WO PCT/US2014/069123 patent/WO2015099989A1/en active Application Filing
- 2014-12-08 PE PE2016000813A patent/PE20160750A1/es unknown
- 2014-12-08 CR CR20160288A patent/CR20160288A/es unknown
- 2014-12-08 JP JP2016560620A patent/JP2017503015A/ja active Pending
- 2014-12-22 AR ARP140104873A patent/AR098929A1/es unknown
- 2014-12-23 UY UY0001035917A patent/UY35917A/es not_active Application Discontinuation
-
2016
- 2016-06-06 IL IL246066A patent/IL246066A0/en unknown
- 2016-06-15 DO DO2016000141A patent/DOP2016000141A/es unknown
- 2016-06-15 CL CL2016001509A patent/CL2016001509A1/es unknown
- 2016-06-20 PH PH12016501203A patent/PH12016501203A1/en unknown
- 2016-06-22 CU CUP2016000096A patent/CU20160096A7/es unknown
- 2016-06-23 MX MX2019005253A patent/MX2019005253A/es unknown
- 2016-06-27 ZA ZA2016/04345A patent/ZA201604345B/en unknown
- 2016-09-06 HK HK16110590.5A patent/HK1222334A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500372A1 (en) | 2020-03-02 |
| PH12016501203B1 (en) | 2016-08-15 |
| JP2017503015A (ja) | 2017-01-26 |
| EA201691029A1 (ru) | 2017-01-30 |
| CA2934799A1 (en) | 2015-07-02 |
| AP2016009254A0 (en) | 2016-06-30 |
| ZA201604345B (en) | 2017-11-29 |
| US9340568B2 (en) | 2016-05-17 |
| AU2014370299A1 (en) | 2016-06-23 |
| IL246066A0 (en) | 2016-07-31 |
| KR20160099710A (ko) | 2016-08-22 |
| MX2016008453A (es) | 2016-10-14 |
| MD20160087A2 (ro) | 2016-12-31 |
| DOP2016000141A (es) | 2016-07-15 |
| CN105873593A (zh) | 2016-08-17 |
| AR098929A1 (es) | 2016-06-22 |
| BR112016013714A8 (pt) | 2020-05-26 |
| MX2019005253A (es) | 2019-08-05 |
| MY178102A (en) | 2020-10-02 |
| PH12016501203A1 (en) | 2016-08-15 |
| US20150175646A1 (en) | 2015-06-25 |
| SG11201604818SA (en) | 2016-07-28 |
| UY35917A (es) | 2015-05-29 |
| EP3086795A1 (en) | 2016-11-02 |
| CU20160096A7 (es) | 2016-11-29 |
| CL2016001509A1 (es) | 2016-12-02 |
| PE20160750A1 (es) | 2016-07-27 |
| HK1222334A1 (zh) | 2017-06-30 |
| TW201609785A (zh) | 2016-03-16 |
| WO2015099989A1 (en) | 2015-07-02 |
| CR20160288A (es) | 2016-08-31 |
| AU2014370299B2 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013714A2 (pt) | compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica | |
| HK1219432A1 (zh) | 以嘧啶化合物爲有效成分的醫藥組合物 | |
| BR112016003229A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112016003454A2 (pt) | Uso de composto de metil bardoxolona | |
| CR20150380A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
| UY35299A (es) | Formulación combinada de dos compuestos antivirales | |
| EP3068517A4 (en) | Compositions of lean nox trap | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| BR112016005262A2 (pt) | Compostos aril éteres, uso dos mesmos e composição farmacêutica que os compreende | |
| BR112016000825A2 (pt) | compostos moduladores de sulfonamidas dos canais de sódio, composição farmacêutica, e uso dos mesmos | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| IL243608A0 (en) | Substances with antiviral activity, preparations containing them and their uses | |
| DK2968529T3 (da) | Fremstilling af jordnøddeformuleringer til oral desensibilisering | |
| DK2968221T3 (da) | Farmaceutisk sammensætning af s-ketaminhydrochlorid | |
| BR112015007310A2 (pt) | compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica | |
| DK2970389T3 (da) | Farmaceutiske forbindelser | |
| DK3043778T3 (da) | Farmaceutiske sammensætninger, der indeholder refametinib | |
| BR112014023200A2 (pt) | uso de uma composição | |
| DK2819648T3 (da) | Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat | |
| BR112014016635A2 (pt) | composto, composição, e, uso de um composto | |
| BR112015016548A2 (pt) | polimixinas , composições , métodos de preparação e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |